C12N 2710/16211
Lymphocryptovirus
Official title: Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
C12N2710/16211 (Lymphocryptovirus) appears on 345 US grants and 390 published applications in this corpus.
Search patents in C12N- Granted patents
- 345
- Published applications
- 390
- Assignees
- 294
- Inventors
- 846
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 4 | 0 |
| 1994 | 9 | 0 |
| 1995 | 8 | 0 |
| 1996 | 7 | 0 |
| 1997 | 13 | 0 |
| 1998 | 28 | 0 |
| 1999 | 10 | 0 |
| 2000 | 18 | 0 |
| 2001 | 11 | 3 |
| 2002 | 16 | 12 |
| 2003 | 11 | 11 |
| 2004 | 9 | 18 |
| 2005 | 3 | 17 |
| 2006 | 7 | 14 |
| 2007 | 5 | 10 |
| 2008 | 10 | 9 |
| 2009 | 5 | 16 |
| 2010 | 13 | 6 |
| 2011 | 9 | 15 |
| 2012 | 4 | 11 |
| 2013 | 7 | 10 |
| 2014 | 7 | 12 |
| 2015 | 5 | 15 |
| 2016 | 7 | 12 |
| 2017 | 8 | 15 |
| 2018 | 11 | 19 |
| 2019 | 16 | 21 |
| 2020 | 11 | 15 |
| 2021 | 11 | 21 |
| 2022 | 8 | 20 |
| 2023 | 10 | 31 |
| 2024 | 18 | 21 |
| 2025 | 10 | 24 |
| 2026 | 7 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16222New viral proteins or individual genes, new structural or functional aspects ofIndexing code246
- C12N 2710/16234Use of virus or viral component as vaccineIndexing code99
- C12N 2710/16241Use of virus, viral particle or viral elements as a vectorIndexing code40
- C12N 2710/16271Demonstrated in vivo effectIndexing code14
- C12N 2710/16261Methods of inactivation or attenuationIndexing code12
- C12N 2710/16223Virus like particles [vlp]Indexing code9
- C12N 2710/16251Methods of production or purification of viral materialIndexing code5
- C12N 2710/16233Use of viral protein as therapeutic agent other than vaccineIndexing code4
Recent patents
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Compositions, devices and methods for inducing immune responses to infectious agents16 Jun 2026US 12,653,888 B2Sigilon Therapeutics, Inc.
- TCR constructs specific for EBV-derived antigens16 Jun 2026US 12,655,191 B2Max-DelbrüCk-Centrum FüR Molekulare Medizin In Der Helmholtz-Gemeinschaft
- LMP-1 expressing cells and methods of use thereof7 Apr 2026US 12,595,285 B2Dana-Farber Cancer Institute, Inc.
- Fusion antibody for presenting antigen-derived T cell antigen epitope or peptide containing same on cell surface, and composition comprising same31 Mar 2026US 12,590,156 B2Ajou University Industry-Academic Cooperation Foundation
- Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof1 Oct 2026US 2026/0295033 A1
- Function-enhanced engineered ebna1 for protein expression in mammalian cells27 Aug 2026US 2026/0250327 A1Wuxi Biologics Ireland Limited
- Epstein-barr virus mrna vaccines6 Aug 2026US 2026/0224691 A1ModernaTX, Inc.
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- New peptides and use thereof as delivery systems for internalization of molecules of interest into target cells9 Jul 2026US 2026/0193297 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Production of recombinant adeno-associated virus vectors369US 5,173,414 AApplied Immune Sciences, Inc. · 1992
- Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse211US 4,879,213 AScripps Clinic and Research Foundation · 1989
- Targeted transfection nanoparticles172US 5,460,831 AThe Regents of the University of California · 1995
- Mammalian interleukin-4156US 5,017,691 ASchering Corporation · 1991